Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

First BCMA-Targeting Therapy Debuts in Multiple Myeloma

January 20th 2021

Sagar Lonial, MD, discussed key facets of belantamab mafodotin and potential next steps.

Dr. Hari on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

January 19th 2021

Parameswaran Hari, MD, MRCP, discusses treatment strategies for patients with relapsed/refractory multiple myeloma.

Dr. Fonseca on Weighing the Risks With Potential Benefits of Quadruplet Regimens in Myeloma

January 18th 2021

Rafael Fonseca, MD, weighs the risks and benefits of quadruplet regimens in patient with multiple myeloma.

Capitalizing on Cellular Therapies in Lymphoma and Myeloma

January 18th 2021

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

DREAMM-2 Trial Regimen Safety Profile

January 18th 2021

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

January 18th 2021

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

January 18th 2021

Dr. Fonseca Discusses Key Data in Multiple Myeloma

January 15th 2021

Rafael Fonseca, MD, discusses key data in multiple myeloma.

Dr. Kumar on Understanding the Safety Profiles of Combination Therapies in Multiple Myeloma

January 15th 2021

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myeloma

January 14th 2021

Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.

INN Melphalan Flufenamide–DEX for Older Patients With RRMM

January 14th 2021

RRMM & High-Risk Cytogenetics: INN Melphalan Flufenamide/DEX

January 14th 2021

RRMM: INN Melphalan Flufenamide/DEX and Extramedullary Disease

January 14th 2021

HORIZON vs MAMMOTH Explored in R/R Multiple Myeloma

January 14th 2021

INN Melphalan Flufenamide in Triple-Class Refractory/Relapsed MM

January 14th 2021

Treatment Advances in Triple-Class Refractory/Relapsed Myeloma

January 14th 2021

Dr. Ailawadhi on the Emergence of T-Cell Engagers in Multiple Myeloma

January 13th 2021

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.

Dr. Lin on CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

January 13th 2021

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

FDA Grants Orphan Drug Designation to BCMA-Targeted TriTAC HPN217 for Myeloma

January 13th 2021

January 13, 2021 — The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct as treatment for patients with multiple myeloma.

Dr. Fonseca on the Emergence of MRD in Multiple Myeloma

January 13th 2021

Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.